Additional information
| Weight | 0.94 oz |
|---|
SAVE 20% Original price was: $45.00.$36.00Current price is: $36.00.
-20%898 in stock
Cyclic heptapeptide melanocortin receptor agonist (MC3R/MC4R). Unlike compounds acting on peripheral vascular mechanisms, PT-141 works through central nervous system melanocortin pathways — specifically hypothalamic circuits involved in arousal signaling. This central mechanism is unique among compounds studied in this research area. Research areas include melanocortin receptor pharmacology, central arousal pathways, hypothalamic signaling, and MC3R/MC4R selectivity profiling. For research use only — not for human consumption.
A new batch of PT-141 10mg is on the way. Samples will be sent to Janoshik upon receipt, and updated COAs will be posted here as results come in.
Due to recent supply chain and international shipping disruptions, some Batch 002 inventory may include vials produced at different points within our supplier’s production cycle. As a result, researchers may notice minor packaging variations, including differences in vial caps.
These products were sourced from the same established manufacturers we have worked with for ongoing quality and third-party testing. That said, we want to be transparent that Batch 002 may not represent a single uninterrupted production run.
We are already working with our suppliers to strengthen batch-control, packaging, and documentation protocols before Batch 003.
| Weight | 0.94 oz |
|---|
Due to recent supply chain and international shipping disruptions, some Batch 002 inventory may include vials produced at different points within our supplier’s production cycle. As a result, researchers may notice minor packaging variations, including differences in vial caps.
These products were sourced from the same established manufacturers we have worked with for ongoing quality and third-party testing. That said, we want to be transparent that Batch 002 may not represent a single uninterrupted production run.
We are already working with our suppliers to strengthen batch-control, packaging, and documentation protocols before Batch 003.